Selection of drug resistance-mediating Plasmodium falciparum genetic polymorphisms by seasonal malaria chemoprevention in Burkina Faso

Antimicrobial Agents and Chemotherapy

Volumn 58, Issue 7, 2014, Pages 3660-3665

  Somé, Anyirékun Fabrice ^a   Zongo, Issaka ^a   Compaoré, Yves Daniel ^a   Sakandé, Souleymane ^b   Nosten, François ^c,d   Ouédraogo, Jean Bosco ^a,b   Rosenthal, Philip J ^e  

^a Public Health Research Institute for Health Sciences   (Burkina Faso)

^b CENTRE MURAZ   (Burkina Faso)

^c MAHIDOL UNIVERSITY   (Thailand)

^d UNIVERSITY OF OXFORD   (United Kingdom)

^e UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIMALARIAL AGENT; DIHYDROARTEMISININ PLUS PIPERAQUINE; FOLIC ACID ANTAGONIST; PYRIMETHAMINE PLUS SULFADOXINE; PROTOZOAL DNA;

ARTICLE; BURKINA FASO; CHEMOPROPHYLAXIS; CONTROLLED STUDY; GENE MUTATION; MALARIA; MALARIA CONTROL; NONHUMAN; PLASMODIUM FALCIPARUM; POLYMERASE CHAIN REACTION; PREVALENCE; PRIORITY JOURNAL; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE; CHILD; DRUG EFFECTS; DRUG RESISTANCE; GENETIC POLYMORPHISM; GENETICS; HUMAN; INFANT; MALARIA, FALCIPARUM; PARASITOLOGY; PRESCHOOL CHILD; RANDOMIZED CONTROLLED TRIAL; RURAL POPULATION; SEASON;

ANTIMALARIALS; BURKINA FASO; CHILD; CHILD, PRESCHOOL; DNA, PROTOZOAN; DRUG RESISTANCE; HUMANS; INFANT; MALARIA, FALCIPARUM; PLASMODIUM FALCIPARUM; POLYMORPHISM, GENETIC; RURAL POPULATION; SEASONS;

EID: 84903151830     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02406-14     Document Type: Article

References (40)

1. Murray CJ, Rosenfeld LC, Lim SS, Andrews KG, Foreman KJ, Haring D, Fullman N, Naghavi M, Lozano R, Lopez AD. 2012. Global malaria mortality between 1980 and 2010: a systematic analysis. Lancet 379:413-431. http://dx.doi.org/10. 1016/S0140-6736(12)60034-8.
2. Aponte JJ, Schellenberg D, Egan A, Breckenridge A, Carneiro I, Critchley J, Danquah I, Dodoo A, Kobbe R, Lell B, May J, Premji Z, Sanz S, Sevene E, Soulaymani-Becheikh R, Winstanley P, Adjei S, Anemana S, Chandramohan D, Issifou S, Mockenhaupt F, Owusu-Agyei S, Greenwood B, Grobusch MP, Kremsner PG, Macete E, Mshinda H, Newman RD, Slutsker L, Tanner M, Alonso P, Menendez C. 2009. Efficacy and safety of intermittent preventive treatment with sulfadoxine-pyrimethamine for malaria in African infants: a pooled analysis of six randomised, placebo-controlled trials. Lancet 374:1533-1542. http://dx.doi.org/10.1016/S0140-6736(09)61258-7.
3. Wilson AL. 2011. A systematic review and meta-analysis of the efficacy and safety of intermittent preventive treatment of malaria in children (IPTc). PLoS One 6:e16976. http://dx.doi.org/10.1371/journal.pone.0016976.
4. Bojang K, Akor F, Bittaye O, Conway D, Bottomley C, Milligan P, Greenwood B. 2010. A randomised trial to compare the safety, tolerability and efficacy of three drug combinations for intermittent preventive treatment in children. PLoS One 5:e11225. http://dx.doi.org/10.1371/journal.pone.0011225.
5. Dicko A, Barry A, Dicko M, Diallo AI, Tembine I, Dicko Y, Dara N, Sidibe Y, Santara G, Conare T, Chandramohan D, Cousens S, Milligan PJ, Diallo DA, Doumbo OK, Greenwood B. 2011. Malaria morbidity in children in the year after they had received intermittent preventive treatment of malaria in Mali: a randomized control trial. PLoS One 6:e23390. http://dx.doi.org/10.1371/journal. pone.0023390.
6. Konaté AT, Yaro JB, Ouédraogo AZ, Diarra A, Gansané A, Soulama I, Kangoyé DT, Kaboré Y, Ouédraogo E, Ouédraogo A, Tiono AB, Ouédraogo IN, Chandramohan D, Cousens S, Milligan PJ, Sirima SB, Greenwood B, Diallo DA. 2011. Intermittent preventive treatment of malaria provides substantial protection against malaria in children already protected by an insecticide-treated bednet in Burkina Faso: a randomised, double-blind, placebo-controlled trial. PLoS Med. 8:e1000408. http://dx.doi.org/10.1371/journal.pmed.1000408.
7. WHO. 2012. WHO policy recommendation: seasonal malaria chemorevention (SMC) for plasmodium falciparum malaria control in highly seasonal transmission areas of the Sahel sub-region in Africa. WHO, Geneva, Switzerland.
8. Smithuis F, Kyaw MK, Phe O, Aye KZ, Htet L, Barends M, Lindegardh N, Singtoroj T, Ashley E, Lwin S, Stepniewska K, White NJ. 2006. Efficacy and effectiveness of dihydroartemisinin-piperaquine versus artesunate-mefloquine in falciparum malaria: an open-label randomised comparison. Lancet 367:2075-2085. http://dx.doi.org/10.1016/S0140-6736(06)68931-9. (Pubitemid 43949291)
9. Hasugian AR, Purba HL, Kenangalem E, Wuwung RM, Ebsworth EP, Maristela R, Penttinen PM, Laihad F, Anstey NM, Tjitra E, Price RN. 2007. Dihydroartemisinin-piperaquine versus artesunate-amodiaquine: superior efficacy and posttreatment prophylaxis against multidrug-resistant Plasmodium falciparum and Plasmodium vivax malaria. Clin. Infect. Dis. 44:1067-1074. http://dx.doi.org/10.1086/512677. (Pubitemid 46580274)
10. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Sere Y, Rosenthal PJ, Ouedraogo JB. 2007. Randomized comparison of amodiaquine plus sulfadoxine-pyrimethamine, artemether-lumefantrine, and dihydroartemisinin- piperaquine for the treatment of uncomplicated Plasmodium falciparum malaria in Burkina Faso. Clin. Infect. Dis. 45:1453-1461. http://dx.doi.org/10.1086/522985. (Pubitemid 351411875)
11. Yeka A, Dorsey G, Kamya MR, Talisuna A, Lugemwa M, Rwakimari JB, Staedke SG, Rosenthal PJ, Wabwire-Mangen F, Bukirwa H. 2008. Artemether-lumefantrine versus dihydroartemisinin-piperaquine for treating uncomplicated malaria: a randomized trial to guide policy in Uganda. PLoS One 3:e2390. http://dx.doi.org/10.1371/journal.pone.0002390.
12. Lwin KM, Phyo AP, Tarning J, Hanpithakpong W, Ashley EA, Lee SJ, Cheah P, Singhasivanon P, White NJ, Lindegardh N, Nosten F. 2012. Randomized, double-blind, placebo-controlled trial of monthly versus bimonthly dihydroartemisinin-piperaquine chemoprevention in adults at high risk of malaria. Antimicrob. Agents Chemother. 56:1571-1577. http://dx.doi.org/10.1128/ AAC.05877-11.
13. Cisse B, Cairns M, Faye E, NDiaye O, Faye B, Cames C, Cheng Y, NDiaye M, Lô AC, Simondon K, Trape JF, Faye O, NDiaye JL, Gaye O, Greenwood B, Milligan P. 2009. Randomized trial of piperaquine with sulfadoxine-pyrimethamine or dihydroartemisinin for malaria intermittent preventive treatment in children. PLoS One 4:e7164. http://dx.doi.org/10.1371/journal.pone.0007164.
14. Bigira V, Kapisi J, Clark TD, Kinara S, Mwangwa F, Muhindo MK, Osterbauer B, Aweeka FT, Huang L, Achan J, Havlir DV, Rosenthal PJ, Kamya MR, Dorsey G. Protective efficacy and safety of three antimalarial regimens for the prevention of malaria in young Ugandan children: a randomized controlled trial. PLoS Med., in press.
15. Nankabirwa JI, Wandera B, Amuge P, Kiwanuka N, Dorsey G, Rosenthal PJ, Brooker SJ, Staedke SG, Kamya MR. 10 March 2014. Impact of intermittent preventive treatment with dihydroartemisinin-piperaquine on malaria in Ugandan schoolchildren: a randomized placebo-controlled trial. Clin. Infect. Dis. http://dx.doi.org/10.1093/cid/ciu150.
16. Ochong EO, van den Broek IV, Keus K, Nzila A. 2003. Short report: association between chloroquine and amodiaquine resistance and allelic variation in the Plasmodium falciparum multiple drug resistance 1 gene and the chloroquine resistance transporter gene in isolates from the upper Nile in southern Sudan. Am. J. Trop. Med. Hyg. 69:184-187.
17. Beshir K, Sutherland CJ, Merinopoulos I, Durrani N, Leslie T, Rowland M, Hallett RL. 2010. Amodiaquine resistance in Plasmodium falciparum malaria in Afghanistan is associated with the pfcrtSVMNTallele at codons 72 to 76. Antimicrob. Agents Chemother. 54:3714-3716. http://dx.doi.org/10.1128/AAC.00358- 10.
18. Ecker A, Lehane AM, Clain J, Fidock DA. 2012. PfCRT and its role in antimalarial drug resistance. Trends Parasitol. 28:504-514. http://dx.doi.org/ 10.1016/j.pt.2012.08.002.
19. Happi CT, Gbotosho GO, Folarin OA, Bolaji OM, Sowunmi A, Kyle DE, Milhous W, Wirth DF, Oduola AM. 2006. Association between mutations in Plasmodium falciparum chloroquine resistance transporter and P. falciparum multidrug resistance 1 genes and in vivo amodiaquine resistance in P. falciparum malaria-infected children in Nigeria. Am. J. Trop. Med. Hyg. 75:155-161. (Pubitemid 351627586)
20. Dokomajilar C, Lankoande ZM, Dorsey G, Zongo I, Ouedraogo JB, Rosenthal PJ. 2006. Roles of specific Plasmodium falciparum mutations in resistance to amodiaquine and sulfadoxine-pyrimethamine in Burkina Faso. Am. J. Trop. Med. Hyg. 75:162-165. (Pubitemid 351627587)
21. Picot S, Olliaro P, de Monbrison F, Bienvenu AL, Price RN, Ringwald P. 2009. A systematic review and meta-analysis of evidence for correlation between molecular markers of parasite resistance and treatment outcome in falciparum malaria. Malar. J. 8:89. http://dx.doi.org/10.1186/1475-2875-8-89.
22. Dorsey G, Dokomajilar C, Kiggundu M, Staedke SG, Kamya MR, Rosenthal PJ. 2004. Principal role of dihydropteroate synthase mutations in mediating resistance to sulfadoxine-pyrimethamine in single-drug and combination therapy of uncomplicated malaria in Uganda. Am. J. Trop. Med. Hyg. 71:758-763. (Pubitemid 40075626)
23. Gregson A, Plowe CV. 2005. Mechanisms of resistance of malaria parasites to antifolates. Pharmacol. Rev. 57:117-145. http://dx.doi.org/10.1124/pr.57.1.4. (Pubitemid 40283971)
24. Mockenhaupt FP, Teun Bousema J, Eggelte TA, Schreiber J, Ehrhardt S, Wassilew N, Otchwemah RN, Sauerwein RW, Bienzle U. 2005. Plasmodium falciparum dhfr but not dhps mutations associated with sulphadoxine-pyrimethamine treatment failure and gametocyte carriage in northern Ghana. Trop. Med. Int. Health 10:901-908. http://dx.doi.org/10.1111/j.1365-3156.2005.01471.x. (Pubitemid 41291231)
25. Zongo I, Dorsey G, Rouamba N, Dokomajilar C, Lankoande M, Ouedraogo JB, Rosenthal PJ. 2005. Amodiaquine, sulfadoxinepyrimethamine, and combination therapy for uncomplicated falciparum malaria: a randomized controlled trial from Burkina Faso. Am. J. Trop. Med. Hyg. 73:826-832. (Pubitemid 41688453)
26. Zongo I, Dorsey G, Rouamba N, Tinto H, Dokomajilar C, Guiguemde RT, Rosenthal PJ, Ouedraogo JB. 2007. Artemether-lumefantrine versus amodiaquine plus sulfadoxine-pyrimethamine for uncomplicated falciparum malaria in Burkina Faso: a randomised non-inferiority trial. Lancet 369:491-498. http://dx.doi.org/10.1016/S0140-6736(07)60236-0. (Pubitemid 46223467)
27. Davis TM, Hung TY, Sim IK, Karunajeewa HA, Ilett KF. 2005. Piperaquine: a resurgent antimalarial drug. Drugs 65:75-87. (Pubitemid 40143802)
28. Somé AF, Séré YY, Dokomajilar C, Zongo I, Rouamba N, Greenhouse B, Ouédraogo JB, Rosenthal PJ. 2010. Selection of known Plasmodium falciparum resistance-mediating polymorphisms by artemether- lumefantrine and amodiaquine-sulfadoxine-pyrimethamine but not dihydroartemisinin-piperaquine in Burkina Faso. Antimicrob. Agents Chemother. 54:1949-1954. http://dx.doi.org/10.1128/AAC.01413-09.
29. Conrad MD, Norbert LeClair N, Arinaitwe E, Wanzira H, Kakuru A, Bigira V, Muhindo M, Kamya MR, Tappero JW, Greenhouse B, Dorsey G, Rosenthal PJ. 8 March 2014. Comparative impacts over 5 years of artemisinin-based combination therapies on P. falciparum polymorphisms that modulate drug sensitivity in Ugandan children. J. Infect. Dis. http://dx.doi.org/10.1093/infdis/jiu141.
30. Plowe CV, Djimde A, Bouare M, Doumbo O, Wellems TE. 1995. Pyrimethamine and proguanil resistance-conferring mutations in Plasmodium falciparum dihydrofolate reductase: polymerase chain reaction methods for surveillance in Africa. Am. J. Trop. Med. Hyg. 52:565-568.
31. Duraisingh MT, Curtis J, Warhurst DC. 1998. Plasmodium falciparum: detection of polymorphisms in the dihydrofolate reductase and dihydropteroate synthetase genes by PCR and restriction digestion. Exp. Parasitol. 89:1-8. http://dx.doi.org/10.1006/expr.1998.4274. (Pubitemid 28377366)
32. Duraisingh MT, Jones P, Sambou I, von Seidlein L, Pinder M, Warhurst DC. 2000. The tyrosine-86 allele of the pfmdr1 gene of Plasmodium falciparum is associated with increased sensitivity to the anti-malarials mefloquine and artemisinin. Mol. Biochem. Parasitol. 108:13-23. http://dx.doi.org/10.1016/ S0166-6851(00)00201-2. (Pubitemid 30236312)
33. Djimdé A, Doumbo OK, Cortese JF, Kayentao K, Doumbo S, Diourté Y, Coulibaly D, Dicko A, Su XZ, Nomura T, Fidock DA, Wellems TE, Plowe CV. 2001. A molecular marker for chloroquine-resistant falciparum malaria. N. Engl. J. Med. 344:257-263. http://dx.doi.org/10.1056/NEJM200101253440403. (Pubitemid 32108530)
34. Holmgren G, Gil JP, Ferreira PM, Veiga MI, Obonyo CO, Bjorkman A. 2006. Amodiaquine resistant Plasmodium falciparum malaria in vivo is associated with selection of pfcrt 76T and pfmdr1 86Y. Infect. Genet. Evol. 6:309-314. http://dx.doi.org/10.1016/j.meegid.2005.09.001. (Pubitemid 43785813)
35. Djimdé AA, Fofana B, Sagara I, Sidibe B, Toure S, Dembele D, Dama S, Ouologuem D, Dicko A, Doumbo OK. 2008. Efficacy, safety, and selection of molecular markers of drug resistance by two ACTs in Mali. Am. J. Trop. Med. Hyg. 78:455-461. (Pubitemid 351845197)
36. Nawaz F, Nsobya SL, Kiggundu M, Joloba M, Rosenthal PJ. 2009. Selection of parasites with diminished drug susceptibility by amodiaquine-containing antimalarial regimens in Uganda. J. Infect. Dis. 200:1650-1657. http://dx.doi.org/10.1086/647988.
37. Happi CT, Gbotosho GO, Folarin OA, Sowunmi A, Hudson T, O'Neil M, Milhous W, Wirth DF, Oduola AM. 2009. Selection of Plasmodium falciparum multidrug resistance gene 1 alleles in asexual stages and gametocytes by artemether-lumefantrine in Nigerian children with uncomplicated falciparum malaria. Antimicrob. Agents Chemother. 53:888-895. http://dx.doi.org/10.1128/ AAC.00968-08.
38. Humphreys GS, Merinopoulos I, Ahmed J, Whitty CJ, Mutabingwa TK, Sutherland CJ, Hallett RL. 2007. Amodiaquine and artemether-lumefantrine select distinct alleles of the Plasmodium falciparum mdr1 gene in Tanzanian children treated for uncomplicated malaria. Antimicrob. Agents Chemother. 51:991-997. http://dx.doi.org/10.1128/AAC.00875-06. (Pubitemid 46355285)
39. Baliraine FN, Rosenthal PJ. 2011. Prolonged selection of pfmdr1 polymorphisms after treatment of falciparum malaria with artemether-lumefantrine in Uganda. J. Infect. Dis. 204:1120-1124. http://dx.doi.org/10.1093/infdis/ jir486.
40. Ord R, Alexander N, Dunyo S, Hallett R, Jawara M, Targett G, Drakeley CJ, Sutherland CJ. 2007. Seasonal carriage of pfcrt and pfmdr1 alleles in Gambian Plasmodium falciparum imply reduced fitness of chloroquine-resistant parasites. J. Infect. Dis. 196:1613-1619. http://dx.doi.org/10.1086/522154. (Pubitemid 351411958)